14 September, 2017
The stock rose 0.07% or $0.05 reaching $76.45 per share.
About 445,309 shares traded. Sage Therapeutics Inc now has $3.31B valuation. It has outperformed by 99.75% the S&P500.
SAGE Therapeutics Inc. (NASDAQ: SAGE) share prices fell heavily after the company disclosed that its Phase 3 STATUS trial of brexalonone in super-refractory status epilepticus (SRSE) did not meet its primary endpoint. About 498 shares traded. (NYSE:JPM) has risen 33.74% since September 12, 2016 and is uptrending. It has outperformed by 16.34% the S&P500. Sage Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $79.79. SAGE was included in 27 notes of analysts from September 3, 2015. H.C. Wainwright downgraded the stock to "Neutral" rating in Wednesday, February 22 report. On Thursday, August 3 the stock rating was maintained by BMO Capital Markets with "Buy".
Whereas they predicted High and Low Earnings Estimate as $-1.7 and $-2.09 respectively. The stock of SAGE Therapeutics Inc (NASDAQ:SAGE) has "Buy" rating given on Thursday, June 23 by H.C. Wainwright. The firm has "Neutral" rating by Goldman Sachs given on Monday, January 11.
According to the Recommendation Trends of the stock polled by Finviz, the company has a consensus recommendation of 1.7 out of the scale from 1 to 5 where 1 stands for Buy and 5 means Sell. Atlantic Trust Group Llc who had been investing in Teva Pharmaceutical Inds Ltd Adr for a number of months, seems to be less bullish one the $19.19 billion market cap company.
Investors sentiment increased to 1.48 in 2016 Q4. A stock with a beta between 0.0 and 1.0 has smaller ups and downs. It dived, as 17 investors sold SAGE Therapeutics Inc shares while 41 reduced holdings. 166 funds opened positions while 553 raised stakes. Blackrock Advsrs Limited has 147,314 shares. Bnp Paribas Arbitrage Sa holds 1.11 million shares. FMR LLC boosted its holdings in shares of Sage Therapeutics by 0.3% in the first quarter. 90,000 are held by Sphera Funds Management. Vanguard Group Inc. now owns 2,691,275 shares of the biopharmaceutical company's stock worth $191,269,000 after purchasing an additional 261,759 shares during the period. Deutsche Bancorporation Ag owns 903,635 shares or 0.04% of their USA portfolio. The company was initiated on Tuesday, September 13 by Raymond James.
TRADEMARK VIOLATION NOTICE: "J P Morgan Chase & Co Lowers Sage Therapeutics, Inc". Pictet Asset Mgmt has invested 0.06% in SAGE Therapeutics Inc (NASDAQ:SAGE).
Covering sell-side analysts have recently weighed in on shares of Sage Therapeutics, Inc. Blackrock Institutional Trust Na reported 782,105 shares. 1,947 were accumulated by Royal National Bank Of Canada. Lake Street initiated the shares of SAGE in report on Friday, March 11 with "Buy" rating. Therefore 94% are positive. The rating was maintained by Leerink Swann on Tuesday, June 20 with "Buy".
The company's shares, which closed at $88.52 on Monday, were down at $68.35 in premarket trading on Tuesday. As per Wednesday, October 28, the company rating was maintained by Imperial Capital.
The stock of Under Armour Inc (NYSE:UA) is a huge mover today! The firm has "Buy" rating by Oppenheimer given on Tuesday, July 25. An increasing ROE indicates that a company is improving its ability to make profit without requiring as much capital. Cowen & Co maintained the shares of TEVA in report on Wednesday, April 5 with "Outperform" rating. The firm has "Buy" rating given on Thursday, August 3 by BMO Capital Markets. Its down 0.12, from 1 in 2016Q3. Creative Planning invested in 100 shares. 45 funds opened positions while 118 raised stakes. Gemmer Asset Limited Liability Corporation accumulated 121 shares or 0.01% of the stock. Principal Fincl Grp Inc stated it has 0% of its portfolio in SAGE Therapeutics Inc (NASDAQ:SAGE). Yorktown Management & Co invested 0.08% of its portfolio in Waste Connections Inc (USA) (NYSE:WCN). Deutsche Fincl Bank Ag reported 903,635 shares or 0.04% of all its holdings.